They found that PD-1+ Vγ9Vδ2 T cells in breast cancer patients produced less IFNγ had lower cytotoxic activity and CD107 degranulation than PD-1− cells after challenging with PD-L1+ tumor target cells. The gene discussed is PDCD1; the disease is breast carcinoma.